[go: up one dir, main page]

DK3668513T3 - Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme - Google Patents

Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme Download PDF

Info

Publication number
DK3668513T3
DK3668513T3 DK18779068.8T DK18779068T DK3668513T3 DK 3668513 T3 DK3668513 T3 DK 3668513T3 DK 18779068 T DK18779068 T DK 18779068T DK 3668513 T3 DK3668513 T3 DK 3668513T3
Authority
DK
Denmark
Prior art keywords
chinase
pyruvat
activities
treatment
blood diseases
Prior art date
Application number
DK18779068.8T
Other languages
English (en)
Inventor
Giovanni Cianchetta
Tao Liu
Anil Kumar Padyana
Zhihua Sui
Zhenwei Cai
Dawei Cui
Jingjing Ji
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3668513T3 publication Critical patent/DK3668513T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK18779068.8T 2017-08-15 2018-08-15 Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme DK3668513T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2017097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
PCT/US2018/000128 WO2019035864A1 (en) 2017-08-15 2018-08-15 PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS

Publications (1)

Publication Number Publication Date
DK3668513T3 true DK3668513T3 (da) 2022-01-10

Family

ID=63524352

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18766400.8T DK3668512T3 (da) 2017-08-15 2018-08-15 Pyruvatkinasemodulatorer og anvendelse deraf
DK18779068.8T DK3668513T3 (da) 2017-08-15 2018-08-15 Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK18766400.8T DK3668512T3 (da) 2017-08-15 2018-08-15 Pyruvatkinasemodulatorer og anvendelse deraf

Country Status (34)

Country Link
US (8) US11590132B2 (da)
EP (4) EP4026838A1 (da)
JP (5) JP7301040B2 (da)
KR (3) KR102764124B1 (da)
CN (3) CN111032046B (da)
AU (4) AU2018316588B2 (da)
BR (2) BR112020003254A2 (da)
CA (2) CA3072455A1 (da)
CL (1) CL2020000375A1 (da)
CO (2) CO2020002961A2 (da)
CR (1) CR20200123A (da)
CY (1) CY1124953T1 (da)
DK (2) DK3668512T3 (da)
EC (1) ECSP20018487A (da)
ES (3) ES2905100T3 (da)
FI (1) FI3668512T3 (da)
HR (2) HRP20220039T1 (da)
HU (2) HUE057178T2 (da)
IL (3) IL272599B (da)
LT (2) LT3668513T (da)
MD (1) MD3668513T2 (da)
MX (2) MX2020001833A (da)
MY (1) MY204421A (da)
PE (1) PE20200724A1 (da)
PH (1) PH12020500343B1 (da)
PL (2) PL3668513T3 (da)
PT (2) PT3668513T (da)
RS (2) RS62871B1 (da)
SG (2) SG11202001262QA (da)
SI (2) SI3668513T1 (da)
SM (2) SMT202300146T1 (da)
TW (3) TWI796353B (da)
UA (1) UA126292C2 (da)
WO (3) WO2019035863A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102007135B1 (ko) 2017-03-20 2019-08-02 포르마 세라퓨틱스 인크. 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물
LT3668513T (lt) 2017-08-15 2022-03-25 Agios Pharmaceuticals, Inc. Piruvatkinazės aktyvatoriai, skirti panaudoti kraujo sutrikimų gydymui
EP3697354A4 (en) 2017-10-20 2021-06-30 The Regents of The University of Michigan EYE DISEASE COMPOSITIONS AND METHODS
CN113166060B (zh) 2018-09-19 2024-01-09 诺沃挪第克健康护理股份公司 用丙酮酸激酶激活化合物治疗镰状细胞病
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
CN113646050A (zh) * 2019-02-13 2021-11-12 安吉奥斯医药品有限公司 噻吩并[3,2-b]吡咯[3,2-d]哒嗪酮衍生物和其作为用于治疗癌症、肥胖和糖尿病相关病症的pkm2衍生物的用途
CN114008147B (zh) * 2019-06-26 2023-05-02 日产化学株式会社 电荷传输性清漆
EP4617276A3 (en) 2019-09-19 2025-11-26 Novo Nordisk Health Care AG Pyruvate kinase r (pkr) activating compositions
US20230374017A1 (en) * 2020-07-21 2023-11-23 The Regents Of The University Of Michigan Compositions and methods for activating pyruvate kinase
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
US11566030B2 (en) 2021-02-08 2023-01-31 Global Blood Therapeutics, Inc. Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN118139864A (zh) * 2021-09-30 2024-06-04 西特瑞治疗有限公司 新化合物
US20250108049A1 (en) * 2021-11-16 2025-04-03 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions
CN116159061A (zh) * 2023-03-09 2023-05-26 上海市第十人民医院 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用
WO2024238659A1 (en) 2023-05-15 2024-11-21 Agios Pharmaceuticals, Inc. Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
WO2025010390A1 (en) * 2023-07-05 2025-01-09 Agios Pharmaceuticals, Inc. Synthesis of pyruvate kinase activators
WO2025207563A1 (en) 2024-03-27 2025-10-02 Agios Pharmaceuticals, Inc. Use of a pk activator in the treatment of sickle cell disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
CN1193026C (zh) 1999-07-30 2005-03-16 艾博特股份有限两合公司 2－吡唑啉－5－酮
HK1045496B (en) 1999-09-04 2004-10-21 Astrazeneca Ab Substituted N-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropionamide derivatives that increase pyruvate dehydrogenase activity
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
KR20110033299A (ko) * 2008-07-23 2011-03-30 버텍스 파마슈티칼스 인코포레이티드 트리-사이클릭 피라졸로피리딘 키나제 억제제
US8420649B2 (en) * 2008-08-29 2013-04-16 Amgen Inc. Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
EP2344453B1 (en) * 2008-10-09 2016-12-28 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
CA2758071C (en) * 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
CN102481300B (zh) 2009-06-29 2015-04-15 安吉奥斯医药品有限公司 治疗性化合物和组合物
JP2013525438A (ja) 2010-04-29 2013-06-20 アメリカ合衆国 ヒトピルビン酸キナーゼ活性剤
EA023796B1 (ru) 2010-12-06 2016-07-29 Глэксо Груп Лимитед ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
PT2704721T (pt) 2011-05-03 2018-06-14 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
US9388164B2 (en) * 2011-05-03 2016-07-12 Agios Pharmaceuticals, Inc Methods of using pyruvate kinase activators
CA2834692A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
EP3372230B1 (en) 2011-05-03 2020-08-12 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
HK1198443A1 (en) * 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
US20140249150A1 (en) * 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
US9921221B2 (en) 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
WO2014074848A1 (en) 2012-11-08 2014-05-15 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions and their use as pkm2 modulators
WO2014118135A1 (en) * 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
NZ712180A (en) * 2013-03-13 2017-01-27 Flatley Discovery Lab Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
WO2014139144A1 (en) * 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
CN120647572A (zh) 2017-07-07 2025-09-16 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
LT3668513T (lt) 2017-08-15 2022-03-25 Agios Pharmaceuticals, Inc. Piruvatkinazės aktyvatoriai, skirti panaudoti kraujo sutrikimų gydymui
PE20200758A1 (es) 2017-08-15 2020-07-27 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
JP2020531433A (ja) 2017-08-15 2020-11-05 アッヴィ・インコーポレイテッド 大環状ｍｃｌ−１阻害剤及び使用の方法
AR112690A1 (es) 2017-08-15 2019-11-27 Agios Pharmaceuticals Inc Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CN113646050A (zh) * 2019-02-13 2021-11-12 安吉奥斯医药品有限公司 噻吩并[3,2-b]吡咯[3,2-d]哒嗪酮衍生物和其作为用于治疗癌症、肥胖和糖尿病相关病症的pkm2衍生物的用途

Also Published As

Publication number Publication date
CA3072455A1 (en) 2019-02-21
EP3668513A1 (en) 2020-06-24
CN117186119A (zh) 2023-12-08
IL292530B2 (en) 2023-06-01
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
PT3668512T (pt) 2023-05-22
PL3668512T3 (pl) 2023-06-19
KR20230127364A (ko) 2023-08-31
AU2024205818A1 (en) 2024-09-05
SMT202300146T1 (it) 2023-07-20
JP7275107B2 (ja) 2023-05-17
AU2018316588B2 (en) 2023-02-02
JP2023027276A (ja) 2023-03-01
WO2019035865A8 (en) 2019-03-28
CR20200123A (es) 2020-06-29
AU2023202772A1 (en) 2023-05-18
KR20200054200A (ko) 2020-05-19
TWI796353B (zh) 2023-03-21
CL2020000375A1 (es) 2020-12-11
HRP20230452T1 (hr) 2023-07-21
WO2019035863A8 (en) 2019-03-28
US11590132B2 (en) 2023-02-28
EP3668881B1 (en) 2023-10-04
SMT202200023T1 (it) 2022-03-21
JP7530453B2 (ja) 2024-08-07
CO2020002961A2 (es) 2020-04-13
CO2020002959A2 (es) 2020-04-13
TW202323258A (zh) 2023-06-16
KR102717594B1 (ko) 2024-10-14
UA126292C2 (uk) 2022-09-14
JP2023052478A (ja) 2023-04-11
BR112020003254A2 (pt) 2020-10-27
MX2020001833A (es) 2020-07-22
ES2905100T3 (es) 2022-04-07
CN111032045B (zh) 2023-08-15
SG11202001353PA (en) 2020-03-30
PH12020500343B1 (en) 2024-02-21
US11364240B2 (en) 2022-06-21
WO2019035864A1 (en) 2019-02-21
IL272599A (en) 2020-03-31
SG11202001262QA (en) 2020-03-30
US20210130371A1 (en) 2021-05-06
AU2018316587A1 (en) 2020-02-20
RS62871B1 (sr) 2022-02-28
WO2019035864A8 (en) 2019-03-28
HRP20220039T1 (hr) 2022-04-15
IL272597A (en) 2020-03-31
IL292530A (en) 2022-06-01
FI3668512T3 (fi) 2023-05-12
CN111032046A (zh) 2020-04-17
CY1124953T1 (el) 2023-01-05
KR102642408B1 (ko) 2024-02-28
RU2020110573A3 (da) 2021-12-24
US20250144093A1 (en) 2025-05-08
TW201920203A (zh) 2019-06-01
EP3668512B1 (en) 2023-02-15
PL3668513T3 (pl) 2022-03-21
US20210077490A1 (en) 2021-03-18
EP3668512A1 (en) 2020-06-24
RU2020110573A (ru) 2021-09-16
EP3668881A1 (en) 2020-06-24
CN111032046B (zh) 2023-09-26
AU2018316587B2 (en) 2023-05-11
TW201919631A (zh) 2019-06-01
JP2020531443A (ja) 2020-11-05
DK3668512T3 (da) 2023-05-22
SI3668513T1 (sl) 2022-04-29
JP2024147805A (ja) 2024-10-16
TWI790271B (zh) 2023-01-21
MX2020001832A (es) 2020-07-22
RS64221B1 (sr) 2023-06-30
AU2023202772B2 (en) 2024-05-16
US11040036B2 (en) 2021-06-22
EP4026838A1 (en) 2022-07-13
JP2020531432A (ja) 2020-11-05
US20230226055A1 (en) 2023-07-20
HUE061910T2 (hu) 2023-08-28
US20220233541A1 (en) 2022-07-28
US11872225B2 (en) 2024-01-16
IL272597B (en) 2022-06-01
KR102764124B1 (ko) 2025-02-05
HUE057178T2 (hu) 2022-04-28
MY204421A (en) 2024-08-28
US20200207785A1 (en) 2020-07-02
EP3668513B1 (en) 2021-11-10
PH12020500343A1 (en) 2021-02-08
ES2966825T3 (es) 2024-04-24
SI3668512T1 (sl) 2023-06-30
IL272599B (en) 2022-08-01
US20200206225A1 (en) 2020-07-02
LT3668512T (lt) 2023-06-12
KR20200054199A (ko) 2020-05-19
JP7301040B2 (ja) 2023-06-30
WO2019035863A1 (en) 2019-02-21
ECSP20018487A (es) 2020-05-29
BR112020003262A2 (pt) 2020-09-01
US11464775B2 (en) 2022-10-11
WO2019035865A1 (en) 2019-02-21
CN111032045A (zh) 2020-04-17
CA3071993A1 (en) 2019-02-21
LT3668513T (lt) 2022-03-25
MD3668513T2 (ro) 2022-04-30
PE20200724A1 (es) 2020-07-21
AU2018316588A1 (en) 2020-02-20
US20220395503A1 (en) 2022-12-15
ES2944545T3 (es) 2023-06-22
US12133853B2 (en) 2024-11-05
US11957680B2 (en) 2024-04-16

Similar Documents

Publication Publication Date Title
DK3668513T3 (da) Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
EP3919049C0 (en) RAPAMYCIN AND METFORMIN COMBINATIONS AND JOINT FOR THE TREATMENT OF JOINT AND SKIN DISEASES
DK3377637T3 (da) Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden
EP3359171C0 (en) Use of akkermansia muciniphila for treating inflammatory conditions
IL255119B (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3024497T3 (da) Fremgangsmåder og præparater til behandling af hjernesygdomme
DK3442580T3 (da) Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3294345T3 (da) Tpp1-formuleringer og fremgangsmåder til behandling af cln2-sygdom
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3439663T3 (da) Fremgangsmåder til behandling af pædiatriske cancere
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
DK3391902T5 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
IL269083A (en) Methods for preventing and treating heart disease
EP3458836C0 (en) NON-INVASIVE BLOOD ANALYSIS
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
DK3157522T3 (da) Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste
HUE057257T2 (hu) Folyékony készítmény gyomor- és nyelõcsõ reflux kezelésében történõ alkalmazásra